Amgen’s Martin to succeed Lee as Gilead’s EVP of research; plus Medicxi, Bavarian Nordic, Antengene, Arcutis and CASI

Gilead Sciences Inc. (NASDAQ:GILD) hired Amgen Inc. (NASDAQ:AMGN) vet Flavius Martin as EVP of research to succeed William Lee, who is retiring after a 30-year tenure with the big biotech. Martin, who most recently served as Amgen’s VP of oncology, inflammation and cardio-metabolic research, brings experience in advancing bispecific T cell engagers and targeted therapies, which are seeing a resurgence of investor enthusiasm this year. Gilead’s cancer pipeline is weighted towards cell therapies and immuno-oncology agents. 

Moncef Slaoui stepped down as a partner at Medicxi Ventures following his termination as Galvani Bioelectronics Ltd.’s chairman. ...